Multiple monitored electroconvulsive therapy
This article was originally published in The Gray Sheet
CMS' Nov. 19 decision not to cover MMECT follows a 1December 2001 HHS Office of the Inspector General report which concluded that the procedure is being used too frequently (2"The Gray Sheet" Jan. 14, 2002, p. 32). The agency found that literature supporting the use of MMECT "reflected substantial methodological shortcomings." In addition, evidence concluded that MMECT may pose additional safety risks over conventional one-time ECT for patients with affective disorders or other psychiatric disorders without a balancing clinical benefit, the decision memorandum states. The agency says it is open to considering evidence for narrowly defined, non-routine uses of MMECT if it is brought to CMS' attention in the future; however, no comments from professional organizations or the general public were submitted during the course of the review...
You may also be interested in...
The Centers for Medicare & Medicaid Services will evaluate the appropriateness of multiple-monitored electroconvulsive therapy in its April review of CPT codes, following a December 2001 recommendation by the HHS Office of the Inspector General
Despite so many COVID-19 uncertainties, e.l.f. Beauty has the confidence of a company that posted 6% net sales growth to $283m for the 2020 fiscal year ended on 31 March and is seeing its value proposition for "prestige-quality" cosmetics resonate even more powerfully with consumers in today’s volatile economic climate.
Latest warning to Humaworm notes findings that FDA inspectors made in July 2019. FDA officials apparently have been in Humaworm’s facility since then, executing a search warrant in October and confiscating encapsulating machines, herbs, capsules, computers, and records.